| __timestamp | BioMarin Pharmaceutical Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 12665000 |
| Thursday, January 1, 2015 | 152008000 | 20202000 |
| Friday, January 1, 2016 | 209620000 | 32407000 |
| Sunday, January 1, 2017 | 241786000 | 35219000 |
| Monday, January 1, 2018 | 315264000 | 36386000 |
| Tuesday, January 1, 2019 | 359466000 | 43081000 |
| Wednesday, January 1, 2020 | 524272000 | 39330000 |
| Friday, January 1, 2021 | 470515000 | 43283000 |
| Saturday, January 1, 2022 | 483669000 | 48316000 |
| Sunday, January 1, 2023 | 577065000 | 54634000 |
| Monday, January 1, 2024 | 580235000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, cost efficiency is a critical metric. Over the past decade, BioMarin Pharmaceutical Inc. and MiMedx Group, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, BioMarin's cost of revenue surged by approximately 345%, reflecting its aggressive expansion and investment in research and development. In contrast, MiMedx Group's cost of revenue increased by about 331%, indicating a more conservative growth strategy.
BioMarin's peak in 2023, with a cost of revenue nearing 578 million, underscores its commitment to innovation, while MiMedx's steady rise to 54.6 million highlights its focus on sustainable growth. This comparison not only illustrates the diverse strategies within the pharmaceutical sector but also emphasizes the importance of balancing cost efficiency with growth ambitions.
Analyzing Cost of Revenue: Pfizer Inc. and MiMedx Group, Inc.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Neurocrine Biosciences, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Incyte Corporation and MiMedx Group, Inc.'s Expenses
Cost Insights: Breaking Down Viatris Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Evotec SE's Expenses
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc. Trends and Insights
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and MiMedx Group, Inc.